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Abstract
Background: Persecutory delusions (strong unfounded fears that others intend harm to the person) occur in more
than 70 % of the patients diagnosed with schizophrenia. This major psychotic experience is a key clinical target, for
which substantial improvement in treatment is needed. Our aim is to use advances in theoretical understanding to
develop a much more efficacious treatment that leads to recovery in at least 50 % of people with persistent
persecutory delusions. Our cognitive conceptualisation is that persecutory delusions are threat beliefs, developed
in the context of genetic and environmental risk, maintained by a number of psychological processes including
excessive worry, low self-confidence, intolerance of anxious affect and other internal anomalous experiences,
reasoning biases, and safety-seeking strategies. The clinical implication is that safety has to be relearned, by
entering the feared situations after reduction of the influence of the maintenance factors. We have been individually
evaluating modules targeting causal factors. These will now be tested together as a full treatment, called The Feeling
Safe Programme. The treatment is modular, personalised, and includes patient preference. We will test whether the
new treatment leads to greater recovery in persistent persecutory delusions, psychological well-being, and
activity levels compared to befriending (that is, controlling for therapist attention).
Methods/design: The Feeling Safe Study is a parallel group randomised controlled trial for 150 patients who have
persecutory delusions despite previous treatment in mental health services. Patients will be randomised (1:1 ratio) to
The Feeling Safe Programme or befriending (both provided in 20 sessions over 6 months). Standard care will continue
as usual. Online randomisation will use a permuted blocks algorithm, with randomly varying block size, stratified by
therapist. Assessments, by a rater blind to allocation, will be conducted at 0, 6 (post treatment), and 12 months. The
primary outcome is the level of delusional conviction at 6 months. Secondary outcomes include levels of psychological
well-being, suicidal ideation, and activity. All main analyses will be intention-to-treat. The trial is funded by the NHS
National Institute for Health Research.
Discussion: The Feeling Safe study will provide a Phase II evaluation of a new targeted translational psychological
treatment for persecutory delusions.
Trial registration: Current Controlled Trials ISRCTN18705064 (registered 11 November 2015).
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Background
Persecutory delusions, a central problem in schizophrenia,
are unfounded beliefs that others are trying to harm the
person [1]. Nearly half of patients with persecutory delu-
sions have major depression [2]. Persecutory delusions
predict serious violence [3], suicide [4], and hospital ad-
mission [5]. It is well-recognised that treatments for perse-
cutory delusions need significant improvement. The first
line treatment, medication has effect sizes (standardised
mean differences) varying between 0.33 and 0.88 (median
= 0.44) [6], with problems of major side effects, poor com-
pliance, and residual symptoms. In a review, Kennedy et
al. [7] found that ‘almost 60 % of patients failed to achieve
response after 23 weeks on antipsychotic drug therapy’.
Meta-analysis for first generation psychological treatment
(when added to medication) indicates an effect size of only
0.36 for delusions [8]. Psychological treatment is a valued
treatment choice for patients, but problems of availability
exist. For instance, in the United Kingdom only about
5 to 10 % of patients receive cognitive behavioural
therapy (CBT) for psychosis [9]. Using advances in the
understanding of the causes of persecutory delusions,
our team have been developing a new targeted modular
psychological treatment - called ‘The Feeling Safe
Programme’ - with the aim of improving efficacy and
deliverability.
The translational studies leading to the trial
At the core of a persecutory delusion is the belief that
the person is unsafe [10]. New research shows that the
heritability of paranoid thoughts is 50 % [11], indicating
genetic and environmental risk leading to such fears.
Once developed, the beliefs concerning danger are main-
tained by six key factors [12] (see Fig. 1). For example,
worry brings implausible ideas to mind, keeps them
there, and exacerbates the distress; negative self-beliefs
lead the person to feel inferior and vulnerable; subjectively
anomalous internal states (for example, dissociation, unex-
plained anxious arousal, and perceptual disturbances)
provoke fearful explanations; disrupted sleep increases
negative affect, mood dysregulation, and anomalous in-
ternal states; reasoning biases prevent the processing of
alternative explanations; and safety-seeking (defensive) be-
haviours such as avoidance prevent the person receiving
and processing disconfirmatory evidence that he or she is
safe. Therefore treatment needs to target the maintenance
factors before helping the patient to go into everyday situ-
ations and relearn that they are safe.
Our team have been developing and evaluating brief
treatments targeting these maintenance factors. Brief,
manualised interventions have been used in order to
aid the theoretical interpretation, later dissemination,
and the building of a combined treatment. The stron-
gest test has been for reducing worry. A randomised
controlled trial (‘The Worry Intervention Trial’) with
150 patients with persistent persecutory delusions was
completed [13]. This had blind ratings and a 95 %
follow-up rate. Targeting worry, in just six sessions,
significantly reduced both worry and the persecutory
delusions (both effect sizes = 0.5). A mediation analysis
Fig. 1 The maintenance of persecutory delusions [12]
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showed that two-thirds of the reductions in the delu-
sions were due to reductions in worry. There were also
significant increases in psychological well-being and re-
ductions in overall psychiatric symptoms. A pilot ran-
domised controlled trial (‘The Self-Confidence Study’)
with 30 patients with persistent persecutory delusions,
principally used techniques to enhance positive self-beliefs
in order to limit the effects of negative self-beliefs [14].
Ratings were blind, and 100 % of the patients were
followed up. Post treatment improvements were ob-
served in positive self-beliefs (effect size = 1.0) and psy-
chological well-being (effect size = 1.2) and reductions
in negative self-beliefs (effect size = 0.24) and the delu-
sions (effect size = 0.6). An assessor-blind, pilot rando-
mised controlled trial (‘The Better Sleep Trial’) with 50
patients with persistent delusions and hallucinations
showed that sleep can be substantially improved (effect
size = 1.9) and that consequential benefits may exist in the
levels of paranoia (effect size = 0.2) and quality of life
(effect size = 0.5) [15]. A trial with several thousand uni-
versity students with insomnia is now underway that will
have sufficient power to test definitively the relation be-
tween sleep improvement and paranoia [16]. Two recent
randomised controlled studies have shown the benefits of
reducing reasoning biases in patients with delusions [17,
18]. For example, in a pilot clinical study with 31 patients
with persistent delusions, the ‘Thinking Well’ reasoning
intervention led to a reduction in delusional conviction
(effect size = 0.6) compared to standard care [18]. Most re-
cently, we have shown that going into feared situations
(that is, reducing avoidance) while dropping safety-seeking
behaviours that prevent the full processing of disconfirm-
atory evidence reduces delusions to a much greater extent
than exposure alone (effect size = 1.3) [19]. All these ele-
ments have now been combined as part of a full interven-
tion, called The Feeling Safe Programme, delivered in 20
sessions over 6 months. The feasibility of this treatment
has been recently established in a case series, and indica-
tions exist of substantial clinical benefits for the patients
[20]. The Feeling Safe Programme has been developed fur-
ther on the basis of this case series.
The new clinical trial
The primary aim now is to test the efficacy in a single
centre of this new theoretically-driven treatment for per-
secutory delusions. The target group is those at most
need: patients whose delusions have not responded to
current treatment. The Feeling Safe Programme is antici-
pated to lead to 50 % of patients having recovery in persist-
ent persecutory delusions. We will test the intervention
against an equal time receiving befriending (called ‘Feeling
Safe and Supported’) from the same therapists. Befriending
has benefits for patients with psychosis and in the
short-term is comparable to first-generation cognitive-
behavioural psychological therapies for psychosis [21, 22].
This choice of comparison allows us to determine whether
the Feeling Safe Programme has benefits over and above
the extra time spent with a therapist, which is important
to determine for future training needs and service
provision.
The primary outcome will be conviction in the perse-
cutory delusion, testing rates of recovery in the delu-
sions (defined as conviction falling below 50 %, that is,
greater doubt than certainty in the delusion) and di-
mensional reductions in conviction levels. The Feeling
Safe Programme is hypothesized to lead to lower levels
of conviction in the persecutory delusions compared to
befriending. Key secondary hypotheses are that the
Feeling Safe Programme, compared to befriending, will
lead to improved psychological well-being and activity
levels compared to befriending. The Feeling Safe
Programme, compared to befriending, is also predicted
to lead to lower levels of overall paranoia, total delusion
severity, and suicidal ideation. The primary endpoint
will be the 6-month outcomes (that is, post-treatment)
but the persistence of effects at a longer follow-up will
also be tested (12 months).
An explanatory component to the trial will be in-
cluded. We will test whether changes in key mainten-
ance factors (worry, self-beliefs, anomalous experiences,
sleep, reasoning, safety-seeking behaviours) mediate
change in delusions. We will also test whether working
memory, illicit drug use, and levels of anger moderate
treatment effects. We will record all service use, and
other relevant health economic data, in order to carry
out a health economic analysis.
Methods
The trial has received ethical approval from an NHS
Research Ethics Committee (South Central – Oxford B
Research Ethics Committee; ref 15/SC/0508) and has been
registered (Current Controlled Trials ISRCTN18705064).
Informed consent will be obtained from all participants. A
Data Monitoring and Ethics Committee (DMEC), Trial
Steering Committee (TSC), and Patient Advisory Group
(PAG) have been formed.
Design
The design is a parallel group randomised controlled
trial with single blind assessment to test whether the
new psychological treatment will reduce persecutory de-
lusions more effectively than befriending (an attention
control condition) (see Fig. 2). Standard care will be
measured but remain as usual in both groups. Assess-
ments will be carried out at 0, 6 (post treatment), and
12 months.
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Participants
Participants will be sought who have persistent perse-
cutory delusions in the context of non-affective psych-
osis. The inclusion criteria are male or female, aged
16 years or above; persistent (at least 3 months) perse-
cutory delusion (as defined by Freeman and Garety [1]),
held with at least 60 % conviction; and primary diagno-
sis of schizophrenia-spectrum psychosis (non-affective
psychosis). The exclusion criteria are current receipt of
another psychological therapy; insufficient comprehen-
sion of English; primary diagnosis of alcohol, drug, or
personality disorder; in forensic settings; organic syn-
drome; or learning disability. Referrals will be sought
from Oxford Health NHS Foundation Trust and neigh-
bouring NHS Trusts (for example, Northamptonshire
Healthcare NHS Foundation Trust and Berkshire
Healthcare NHS Foundation Trust).
Randomisation and blinding
The trial assessor will be blind to group allocation, but
the patients and trial therapists will not be. Patient con-
sent and assessments will be carried out by the trial
assessor. Randomisation will occur after completion of
the baseline assessment. An online randomisation sys-
tem has been written by the University of Oxford Pri-
mary Care Clinical Trials Unit. Randomisation using a
permuted blocks algorithm, with randomly varying block
size, will be stratified by therapist. Therapists will provide
both interventions in order to reduce the confounding of
therapist effects and increase statistical power. The trial
co-ordinator will use the online system, after being pro-
vided by the trial assessor with basic patient details
(date of birth, gender).
The trial coordinator will inform trial therapists who
will then inform patients of the randomisation outcome,
so that the research assessors remain blind to group
allocation. Precautionary strategies to prevent breaks of
the blind include the following: the patients being
reminded by team members not to talk about treatment
allocation; the assessor not looking at the patient’s
clinical notes after the baseline assessment; and if an
allocation is revealed between assessment sessions, then
re-blinding with another assessor. We envisage conceal-
ment of treatment allocation from the trial assessor will
Fig. 2 Trial flow diagram
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be easier than treatment-as-usual comparison trials be-
cause all patients are receiving a psychological interven-
tion from the same therapists.
Assessments
Basic demographic and clinical data will be collected (for
example, age, gender, ethnicity, and clinical diagnosis).
The primary outcome measure will be conviction in the
persecutory delusion (using a 0 to 100 % scale), assessed
within the Psychotic Symptoms Rating Scale-Delusions
scale [23]. Recovery is defined as the conviction in the de-
lusional belief falling below 50 %; that is, there is greater
doubt than belief in the delusion. Conviction greater than
50 % is a standard definition of the presence of a delusion
(for example, [24]), although such beliefs are typically held
with much greater certainty. For example, in our Feeling
Safe Programme pilot study (n = 12), the initial conviction
levels in the delusions showed a mean of 90 % (SD = 17)
[20], and in a previous study with 100 patients with delu-
sions, the mean conviction rating was 82 % (SD = 20) [25].
In the Worry Intervention Trial, at baseline, half of the
150 patients had 100 % conviction in the persecutory delu-
sions [13].
Psychological well-being will be assessed by the
Warwick-Edinburgh Mental Well-being Scale [26], health
status by the EQ-5D-5 L (see http://www.euroqol.org/),
quality of life by the Long Term Conditions Questionnaire
(LTCQ) [27], and patient satisfaction using an adapted
version of the CHOICE, a service user-led outcome meas-
ure [28]. Activity levels will be assessed using a step count
and a time-budget measure [29]. We will also include
measures of overall paranoia (Green et al. Paranoid
Thoughts Scale) [30], suicidal ideation (Columbia-Suicide
Severity Rating Scale) [31], and depression (Beck Depres-
sion Inventory) [32].
We will include the following as moderators: working
memory [33], illicit drug use [34], and anger (Dimen-
sions of Anger Reactions (DAR-5)) [35]. For mediation,
we will include the following: the Penn State Worry
Questionnaire [36], Brief Core Schema Scales [37],
Specific Psychotic Experiences Questionnaire - halluci-
nations subscale (SPEQ) [38], Insomnia Severity Index
[39], jumping to conclusions [40] and belief flexibility
[18], and the Safety Behaviours Questionnaire – Persecu-
tory Beliefs [41]. We will record service use and other
relevant health economic data using an adapted version of
the Economic Patient Questionnaire [42] (EPQ) that
includes questions from the Client Service Receipt
Inventory [43].
In collaboration with the McPin Foundation, qualita-
tive interviews will be carried out with a small number
of patients and family members about the Feeling Safe
Programme to assess the acceptability of the experimen-
tal intervention.
Adverse events
We will check medical notes at the end of a patient’s
participation for serious adverse events, including but not
limited to: 1. All deaths. 2. Suicide attempts. 3. Violent in-
cidents (needing police involvement) and 4. Formal com-
plaints about therapy. We will also record any such event
that we become aware of during a patient’s participation.
All hospital admission data will also be recorded. The
DMEC will determine relatedness of an event to the trial
based on a temporalrelationship and whether the event is
unexpected or unexplained given the participant’s clinical
course, previous history, and concomitant treatments.
Psychological interventions
Both treatments are provided to patients individually in
approximately 20 sessions over 6 months. Treatments will
be provided by the trial clinical psychologists, with weekly
supervision. The number of sessions and length will be re-
corded, sessions will be taped when patients are agreeable,
and tapes will be rated for fidelity and competence. Patient
beliefs about the potential effectiveness of the intervention
that he or she receives will be assessed after the first
session with the Credibility/Expectancy Questionnaire
[44], and therapeutic empathy will also be assessed
with a patient questionnaire [45].
In The Feeling Safe Programme, following an assess-
ment, the patient is offered a menu of appropriate treat-
ment modules. Typically three to four modules are
completed, based on patient preference. The range of
modules that can be offered are improving sleep, redu-
cing worry, increasing self-confidence, reducing the im-
pact of voices, improving reasoning processes, and
behavioural tests for reducing fear beliefs. Befriending,
called in the trial ‘Feeling Safe and Supported’ will follow
a protocol devised by one of the trial team members
(DK) that has previously been used in two large clinical
trials for patients with psychosis over 20 sessions [21, 22].
Essentially, the aim is to simulate how a good friend would
respond and involves a general focus on non-threatening
topics (although patients are not actively dissuaded from
talking about concerns), non-confrontation, empathy, and
supportiveness.
Statistical and economic analysis plan
A full statistical analysis plan will be written by the trial
statisticians (RE, GD) prior to any analysis being under-
taken. We will report data in line with the Consolidated
Standards of Reporting Trials (CONSORT) 2010 Statement
(http://www.consort-statement.org/consort-2010), showing
attrition rates and loss to follow-up. All analyses will be car-
ried out using the intention-to-treat principle with data
from all participants in the analysis, including those who do
not complete therapy. Every effort will be made to follow
up all participants in both arms for research assessments.
Freeman et al. Trials  (2016) 17:134 Page 5 of 8
Analysis will be conducted in Stata version 14 [46].
Descriptive statistics within each randomised group will
be presented for baseline values. These will include
counts and percentages for binary and categorical vari-
ables and means and standard deviations, or medians
with lower and upper quartiles, for continuous variables,
along with minimum and maximum values and counts
of missing values. There will be no tests of statistical sig-
nificance or confidence intervals for differences between
randomised groups on any baseline variable.
Descriptive statistics will be used to summarize assess-
ments of feasibility and acceptability in terms of recruit-
ment, drop-out, and completeness of therapy.
The primary hypothesis for change in the primary out-
come measure, conviction in the persecutory delusion
(using a 0 to 100 % scale) at 6 months, will be analysed
using a linear regression model allowing for the base-
line measurement of outcome, severity of delusion,
therapist and treatment assignment as fixed effects. To
compare rates of recovery (scores falling below 50 %),
we will use logistic regression models instead of linear
models. Secondary outcome measures will be analysed
using the same modelling approach. This includes ana-
lysis of the primary outcome and secondary outcomes
at 12 months.
The mediation analysis will investigate putative medi-
ational factors using modern causal inference methods
[47, 48]. This involves using parametric regression
models to test for mediation of the Feeling Safe Inter-
vention on outcome through the putative mediators.
Analyses will adjust for baseline measures of the medi-
ator, outcomes, and possible measured confounders.
We will include repeated measurement of mediators
and outcomes to account for classical measurement
error and baseline confounding, and where feasible, use
instrumental variable methods (baseline covariate by
randomization interactions as potential instruments) to
investigate the sensitivity of the estimates to these
problems and that of unmeasured confounding.
Moderators will be assessed separately by repeating
the primary analysis models and including interaction
terms between the randomised intervention and each
moderator. The coefficient of the interaction term is a
measure of whether the treatment effect differs between
levels of the moderator.
Missing data on individual measures will be pro-
rated if more than 90 % of the items are completed;
otherwise the measure will be considered as missing.
We will check for differential predictors of missing
outcomes by comparing responders to non-responders
on key baseline variables. Any significant predictors
will be included in the analysis models. This accounts
for missing outcome data under a missing at random
assumption, conditional on the covariates included in
the model. As a sensitivity analysis, we will assess
whether treatment adherence is associated with miss-
ing data, and if it is associated, use inverse probability
weights or multiple imputation to compare results.
An economic evaluation will estimate the cost per
quality adjusted life year (QALY) gained from a health
and social care perspective over the 1-year timeframe of
the trial. An economic model will be used to explore the
potential cost effectiveness of the intervention over the
patient’s lifetime. A detailed analysis plan for the eco-
nomic evaluation will be prepared by the trial health
economist (LMD) prior to the analysis. This will be in-
formed by exploratory analyses of the pooled baseline
data and published literature.
For a recovery rate in delusions of 50 % in the Feeling
Safe Programme, compared to 20 % with befriending, a
study will have over 90 % power with 60 patients in
each arm. The trial will, however, gain greater power
by also examining change in delusion dimensional
scores. If the standardised effect of the new interven-
tion compared to befriending were smaller than 10
percentage points on the conviction scale (0 to 100 %)
(d = 0.5), then we would not consider further develop-
ment of the intervention to be worth pursuing. If the
true effect size were this ten-point difference (SD = 20),
then a two-sample t-test with a two-sided significance
level of 0.05 would have 80 % power to detect a statis-
tically significant effect with outcome data available for
64 participants per randomised arm. We aim to recruit
75 per arm. This conservatively allows for a drop-out
of 15 %. Allowing for stratum membership and base-
line levels of the measures in a more refined analysis
of covariance will increase both statistical power and
precision.
Discussion
Over the past 15 years, a significant advance has oc-
curred in the understanding of the causes of paranoia.
This research has predominately been from a cognitive
perspective [12,49–52]. The advance in knowledge is be-
ginning to be translated into treatment. From our theor-
etical model, the clinical goal becomes to enable the
patient to form a strong belief concerning current safety,
thereby allowing the persecutory threat belief to dissi-
pate. Hence the influence of the maintenance factors
needs to be reduced and patients re-enter the threatening
situations in order to learn directly that nothing adverse
occurs. Toleration of the high anxiety, associated physio-
logical arousal, and other anomalous experiences needs to
occur. This learning of safety should allow a fundamental
shift of attention away from activation of the negative
valence system. From this perspective, clinical trials need
to recruit patients on the presence of having persecutory
delusions, and such delusions and related behaviours
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should become the main outcome. The Feeling Safe Study
will be such an example. Translating our cognitive model,
a series of studies of persistent persecutory delusions have
shown the benefits of targeting the maintenance factors
individually. The current trial aims to determine the
efficacy, above that of simple therapist effects, of a full
treatment based on the theoretical understanding. The
potential is a substantial improvement in treatment for
persistent persecutory delusions. Outcome results are
expected in 2020.
Trial status
The trial is due to start patient recruitment in February
2016.
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